Erratum for Asempa et al., “*In Vitro* Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against *Pseudomonas aeruginosa*”

Tomefa E. Asempa,^a David P. Nicolau,^{a,b} Joseph L. Kuti^a

^aCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

^bDivision of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Volume 63, no. 9, e00997-19, 2019, <https://doi.org/10.1128/AAC.00997-19>. Tables 1 and 2: the isolate in row 3 of each of these tables should be CDC0526 and the isolate in row 9 should be CDC0508. Both of these isolates were obtained from the FDA-CDC Antimicrobial Resistance Isolate Bank (Atlanta, GA).

Figure 1, panel c, the isolate designation should read “CDC Bank #0526.”

Figure 2, panel e, the isolate designation should read “CDC Bank #0508.”

Citation Asempa TE, Nicolau DP, Kuti JL. 2020. Erratum for Asempa et al., “*In vitro* activity of imipenem-relebactam alone or in combination with amikacin or colistin against *Pseudomonas aeruginosa*.” Antimicrob Agents Chemother 64:e00467-20. <https://doi.org/10.1128/AAC.00467-20>.

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Joseph L. Kuti, joseph.kuti@hhchealth.org.

Published 21 April 2020